Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-003695-40 | EudraCT Number |
Not provided
Not provided
Administrative decision (not due to safety reason)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Loncastuximab Tesirine | Experimental | Participants will be administered loncastuximab tesirine as an intravenous (IV) infusion on Day 1 of each cycle, where 1 cycle is 3 weeks. Loncastuximab tesirine will be administered at a dose of 150 μg/kg for 2 cycles, then at a dose of 75 μg/kg for subsequent cycles. |
|
| Idelalisib | Active Comparator | Participants will be administered 150 mg idelalisib, orally, twice a day throughout each cycle, where 1 cycle is 4 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Loncastuximab Tesirine | Drug | IV infusion |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Complete Response Rate (CRR) | CRR was defined as the percentage of participants who experienced a best overall response (BOR) of complete response (CR) assessed prior to any subsequent anticancer treatment. | Up to the end of treatment, maximum time on treatment was 333 days |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Response Rate (ORR) | ORR was defined as the percentage of participants with a BOR of CR or partial response (PR) assessed prior to any subsequent anticancer treatment. | Up to end of treatment, maximum time on treatment was 333 days |
| Progression-Free Survival (PFS) |
Not provided
Inclusion Criteria:
Written informed consent must be obtained prior to any study procedures.
Male or female participants aged 18 years or older, with pathologic diagnosis of follicular lymphoma (FL) (Grade 1, 2, 3A) in the most recent tumor biopsy.
Relapsed or refractory disease following two or more treatment regimens, at least one of which must have contained an anti-CD20 therapy.
Participants who have received previous CD19-directed therapy must have a biopsy which shows CD19 expression after completion of the CD19-directed therapy.
Measurable disease as defined by the 2014 Lugano Classification as assessed by positron emission tomography - computed tomography (PET-CT) or, if not Fluorodeoxyglucose (FDG) avid, CT or magnetic resonance imaging (MRI).
Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block (or minimum 10 freshly cut unstained slides if block is not available). Note: Any biopsy since initial diagnosis is acceptable, but if several samples are available, the most recent sample is preferred.
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
Adequate organ function as defined by screening laboratory values within the following parameters:
Women of childbearing potential (WOCBP)(1) must agree to use a highly effective method(2) of contraception from the time of giving informed consent until at least 9 months after the last dose of study treatment. Men with female partners who are of childbearing potential must agree to use a condom when sexually active or practice total abstinence from the time of giving informed consent until at least 6 months after the participant receives his last dose of study treatment.
Note: The double-barrier method (e.g., synthetic condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), periodic abstinence (such as calendar, symptothermal, post ovulation), withdrawal (coitus interruptus), lactational amenorrhea method, and spermicide-only are not acceptable as highly effective methods of contraception.
Exclusion Criteria:
Previous treatment with loncastuximab tesirine.
Previous treatment with idelalisib.
History of hypersensitivity to any of the excipients of loncastuximab tesirine or idelalisib.
Follicular lymphoma which has transformed to diffuse large B-cell lymphoma (DLBCL) or other aggressive lymphomas.
Requires treatment or prophylaxis with a strong cytochrome P450 (CYP) 3A inhibitor, inducer, or sensitive substrate.
History of or ongoing drug-induced pneumonitis.
History of or ongoing inflammatory bowel disease.
Any condition that could interfere with the absorption or metabolism of idelalisib including malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.
Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that the Sponsor's medical monitor and Investigator agree and document should not be exclusionary.
Autologous transplant within 30 days prior to start of study treatment (C1D1).
Allogenic transplant within 60 days prior to start of study treatment (C1D1).
Active graft-versus-host disease.
Post-transplantation lymphoproliferative disorders.
Human immunodeficiency virus (HIV) seropositive with any of the following:
Serologic evidence of chronic hepatitis B infection and unable or unwilling to receive standard prophylactic anti-viral therapy or with detectable hepatitis B virus (HBV) viral load.
Serologic evidence of hepatitis C infection without completion of curative treatment or with detectable hepatitis C virus (HCV) viral load.
History of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Lymphoma with active central nervous system involvement, including leptomeningeal disease.
Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath).
Breastfeeding or pregnant.
Significant medical comorbidities, including but not limited to, uncontrolled hypertension (BP ≥160/100 mm Hg repeatedly), unstable angina, congestive heart failure (greater than New York Heart Association class II), electrocardiographic evidence of acute ischemia, coronary angioplasty or myocardial infarction within 6 months prior to screening, uncontrolled atrial or ventricular cardiac arrhythmia, poorly controlled diabetes, or severe chronic pulmonary disease.
Any Grade ≥3 active infection which requires IV antibiotics, IV antiviral, or IV antifungal treatment.
Major surgery, radiotherapy, chemotherapy or other anti-neoplastic therapy within 14 days prior to start of study treatment (C1D1), except shorter if approved by the Sponsor.
Use of any other experimental medication within 30 days prior to start of study treatment (C1D1).
Live vaccine administration within 4 weeks prior to Cycle(C) 1 Day (D) 1.
Failure to recover to ≤ Grade 1 (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) from acute non-hematologic toxicity (except ≤Grade 2 neuropathy or alopecia) due to previous therapy prior to screening.
Any other significant medical illness, abnormality, or condition that would, in the Investigator's judgment, make the participant inappropriate for study participation or put the participant at risk.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Comprehensive Cancer Centers of Nevada - Central Valley | Las Vegas | Nevada | 89074 | United States | ||
| Comprehensive Cancer Centers of Nevada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Loncastuximab Tesirine | Participants were administered loncastuximab tesirine as an intravenous (IV) infusion on Day 1 of each cycle, where 1 cycle is 3 weeks. Loncastuximab tesirine will be administered at a dose of 150 μg/kg for 2 cycles, then at a dose of 75 μg/kg for subsequent cycles. The median number of treatment cycles was 5.5 (min: 5; max: 12). The median treatment duration was 122.5 days (min: 54; max: 231 days). |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Apr 7, 2021 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Idelalisib | Drug | Oral tablet |
|
PFS was defined as the time between the randomization date and the first documentation of recurrence, progression, or death. |
| Up to end of treatment, maximum time on treatment was 333 days |
| Overall Survival (OS) | OS was defined as the time between the randomization date and death from any cause. | Up to end of treatment, maximum time on treatment was 333 days |
| Duration of Response (DOR) | DOR was defined as the time from the documentation of tumor response to disease progression or death. | Up to end of treatment, maximum time on treatment was 333 days |
| Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) | TEAEs were defined as an AE that occurs or worsens in the period extending from the first dose of study treatment until 30 days after the last dose of study treatment or start of new anti-cancer therapy, whichever is earlier. Any clinically significant changes from baseline in the safety laboratory values, vital signs, 12-lead electrocardiogram (ECG), and Eastern Cooperative Oncology Group (ECOG) performance status were reported as TEAEs. | Day 1 to 30 days after end of treatment, maximum time on treatment was 333 days |
| Average Concentration of Loncastuximab Tesirine Before Infusion | Up to end of treatment, maximum time on treatment was 333 days |
| Average Concentration of Loncastuximab Tesirine at the End of Infusion | Up to end of treatment, maximum time on treatment was 333 days |
| Clearance Rate of Loncastuximab Tesirine | Up to end of treatment, maximum time on treatment was 333 days |
| Volume of Distribution of Loncastuximab Tesirine | Up to end of treatment, maximum time on treatment was 333 days |
| Number of Participants With Anti-Drug Antibody (ADA) Titers to Loncastuximab Tesirine | Up to end of treatment, maximum time on treatment was 333 days |
| Change From Baseline in Health-Related Quality of Life (HRQoL) as Measured by the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) | Up to end of treatment, maximum time on treatment was 333 days |
| Change From Baseline in Health-Related Quality of Life (HRQoL) as Measured by the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) | Up to end of treatment, maximum time on treatment was 333 days |
| Number of Participants With Specific Symptomatic Adverse Event Symptoms As Selected From Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | The specific symptomatic adverse events includes fatigue, swelling, rash, nausea, diarrhea, abdominal pain, and cough. | Up to end of treatment, maximum time on treatment was 333 days |
| Treatment-Related Symptoms as Assessed by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | The specific symptoms assessed include fatigue, swelling, rash, nausea, diarrhea, abdominal pain, and cough. The severity is assessed from "None" to "Very severe" and the interference level is assessed from "Not at all" to "Very much." | Up to end of treatment, maximum time on treatment was 333 days |
| Las Vegas |
| Nevada |
| 89169 |
| United States |
| Summit Medical Group - Florham Park Campus | Florham Park | New Jersey | 07932 | United States |
| Summit Medical Group | Florham Park | New Jersey | 07932 | United States |
| Hollings Cancer Center | Charleston | South Carolina | 29425 | United States |
| Universitair Ziekenhuis Gent | Ghent | 9000 | Belgium |
| Centre Hospitalier Universitaire Universite Catholique de Louvain | Yvoir | B-5530 | Belgium |
| Centre Hospitalier de Dunkerque | Dunkirk | 59385 | France |
| Centre Hospitalier de La Rochelle | La Rochelle | 17000 | France |
| Centre de Lutte Contre le Cancer - Centre Henri-Becquerel | Rouen | 76038 | France |
| Hôpital Bretonneau | Tours | 37044 | France |
| Semmelweis Egyetem | Budapest | 1088 | Hungary |
| Országos Onkológiai Intézet | Budapest | 1122 | Hungary |
| Pécsi Tudományegyetem Klinikai Központ | Pécs | 7624 | Hungary |
| Soroka Medical Center | Beersheba | 8410101 | Israel |
| Carmel Medical Center | Haifa | 3436212 | Israel |
| Rabin Medical Center - Beilinson Hospital | Petah Tikva | 4941492 | Israel |
| The Chaim Sheba Medical Center | Tel Aviv | 52621 | Israel |
| Tel Aviv Sourasky Medical Center | Tel Aviv | 6423906 | Israel |
| Azienda Ospedaliero - Universitaria Careggi | Florence | 50134 | Italy |
| Szpitale Pomorskie Spółka Z Ograniczoną Odpowiedzialnością | Gdynia | 81-519 | Poland |
| Pratia Onkologia Katowice | Katowice | 40-519 | Poland |
| Pratia Poznań | Skorzewo | 60-185 | Poland |
| Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet) | L'Hospitalet de Llobregat | 08908 | Spain |
| Hospital Universitari Arnau de Vilanova | Lleida | 25198 | Spain |
| Hospital Universitario Ramón y Cajal | Madrid | 08908 | Spain |
| Hospital General Universitario Gregorio Marañón | Madrid | 28007 | Spain |
| Hospital Universitario Fundación Jiménez DÃaz | Madrid | 28040 | Spain |
| Hospital Universitario La Paz | Madrid | 28046 | Spain |
| Hospital Universitario Quirónsalud Madrid | Pozuelo de Alarcón | 28223 | Spain |
| Hospital Universitario Virgen del RocÃo | Seville | 41013 | Spain |
| Inselspital Universitätsspital Bern | Bern | 3010 | Switzerland |
| NHS Greater Glasgow and Clyde | Glasgow | G51 4TF | United Kingdom |
| Account University College London Hospitals NHS Foundation Trust | London | NW1 2PG | United Kingdom |
| FG001 | Idelalisib | Participants were administered 150 mg idelalisib, orally, twice a day throughout each cycle, where 1 cycle is 4 weeks. 1 participant received 6 cycles and the other participant received 13 cycles of treatment. The treatment duration was 140 days and 333 days, respectively. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Loncastuximab Tesirine | Participants were administered loncastuximab tesirine as an intravenous (IV) infusion on Day 1 of each cycle, where 1 cycle is 3 weeks. Loncastuximab tesirine was administered at a dose of 150 μg/kg for 2 cycles, then at a dose of 75 μg/kg for subsequent cycles. The median number of treatment cycles was 5.5 (min: 5; max: 12). The median treatment duration was 122.5 days (min: 54; max: 231 days). |
| BG001 | Idelalisib | Participants were administered 150 mg idelalisib, orally, twice a day throughout each cycle, where 1 cycle is 4 weeks. 1 participant received 6 cycles and the other participant received 13 cycles of treatment. The treatment duration was 140 days and 333 days, respectively. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Count of Participants | Participants |
| ||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Complete Response Rate (CRR) | CRR was defined as the percentage of participants who experienced a best overall response (BOR) of complete response (CR) assessed prior to any subsequent anticancer treatment. | No response data was collected. | Posted | Up to the end of treatment, maximum time on treatment was 333 days |
|
| ||||||||||||||||||||||
| Secondary | Overall Response Rate (ORR) | ORR was defined as the percentage of participants with a BOR of CR or partial response (PR) assessed prior to any subsequent anticancer treatment. | No response data was collected. | Posted | Up to end of treatment, maximum time on treatment was 333 days |
|
| ||||||||||||||||||||||
| Secondary | Progression-Free Survival (PFS) | PFS was defined as the time between the randomization date and the first documentation of recurrence, progression, or death. | Inclusive of participants who experienced recurrence, progression, or death. | Posted | Median | Full Range | days | Up to end of treatment, maximum time on treatment was 333 days |
|
| |||||||||||||||||||
| Secondary | Overall Survival (OS) | OS was defined as the time between the randomization date and death from any cause. | Inclusive of participants who experienced death. | Posted | Median | Full Range | days | Up to end of treatment, maximum time on treatment was 333 days |
|
| |||||||||||||||||||
| Secondary | Duration of Response (DOR) | DOR was defined as the time from the documentation of tumor response to disease progression or death. | No response data was collected. | Posted | Up to end of treatment, maximum time on treatment was 333 days |
|
| ||||||||||||||||||||||
| Secondary | Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) | TEAEs were defined as an AE that occurs or worsens in the period extending from the first dose of study treatment until 30 days after the last dose of study treatment or start of new anti-cancer therapy, whichever is earlier. Any clinically significant changes from baseline in the safety laboratory values, vital signs, 12-lead electrocardiogram (ECG), and Eastern Cooperative Oncology Group (ECOG) performance status were reported as TEAEs. | Posted | Count of Participants | Participants | Day 1 to 30 days after end of treatment, maximum time on treatment was 333 days |
| ||||||||||||||||||||||
| Secondary | Average Concentration of Loncastuximab Tesirine Before Infusion | No data was collected. | Posted | Up to end of treatment, maximum time on treatment was 333 days |
|
| |||||||||||||||||||||||
| Secondary | Average Concentration of Loncastuximab Tesirine at the End of Infusion | No data was collected. | Posted | Up to end of treatment, maximum time on treatment was 333 days |
|
| |||||||||||||||||||||||
| Secondary | Clearance Rate of Loncastuximab Tesirine | No data was collected. | Posted | Up to end of treatment, maximum time on treatment was 333 days |
|
| |||||||||||||||||||||||
| Secondary | Volume of Distribution of Loncastuximab Tesirine | No data was collected. | Posted | Up to end of treatment, maximum time on treatment was 333 days |
|
| |||||||||||||||||||||||
| Secondary | Number of Participants With Anti-Drug Antibody (ADA) Titers to Loncastuximab Tesirine | No data was collected. | Posted | Up to end of treatment, maximum time on treatment was 333 days |
|
| |||||||||||||||||||||||
| Secondary | Change From Baseline in Health-Related Quality of Life (HRQoL) as Measured by the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) | No data was collected. | Posted | Up to end of treatment, maximum time on treatment was 333 days |
|
| |||||||||||||||||||||||
| Secondary | Change From Baseline in Health-Related Quality of Life (HRQoL) as Measured by the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) | No data was collected. | Posted | Up to end of treatment, maximum time on treatment was 333 days |
|
| |||||||||||||||||||||||
| Secondary | Number of Participants With Specific Symptomatic Adverse Event Symptoms As Selected From Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | The specific symptomatic adverse events includes fatigue, swelling, rash, nausea, diarrhea, abdominal pain, and cough. | No data was collected. | Posted | Up to end of treatment, maximum time on treatment was 333 days |
|
| ||||||||||||||||||||||
| Secondary | Treatment-Related Symptoms as Assessed by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | The specific symptoms assessed include fatigue, swelling, rash, nausea, diarrhea, abdominal pain, and cough. The severity is assessed from "None" to "Very severe" and the interference level is assessed from "Not at all" to "Very much." | No data was collected. | Posted | Up to end of treatment, maximum time on treatment was 333 days |
|
Up to end of treatment, maximum time on treatment was 333 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Loncastuximab Tesirine | Participants were administered loncastuximab tesirine as an intravenous (IV) infusion on Day 1 of each cycle, where 1 cycle is 3 weeks. Loncastuximab tesirine will be administered at a dose of 150 μg/kg for 2 cycles, then at a dose of 75 μg/kg for subsequent cycles. The median number of treatment cycles was 5.5 (min: 5; max: 12). The median treatment duration was 122.5 days (min: 54; max: 231 days). | 1 | 4 | 3 | 4 | 4 | 4 |
| EG001 | Idelalisib | Participants were administered 150 mg idelalisib, orally, twice a day throughout each cycle, where 1 cycle is 4 weeks. 1 participant received 6 cycles and the other participant received 13 cycles of treatment. The treatment duration was 140 days and 333 days, respectively. | 0 | 2 | 0 | 2 | 2 | 2 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | Non-systematic Assessment |
| ||
| COVID-19 | Infections and infestations | Non-systematic Assessment |
| ||
| COVID-19 pneumonia | Infections and infestations | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Alanine aminotransferase increased | Investigations | Non-systematic Assessment |
| ||
| Aspartate aminotransferase increased | Investigations | Non-systematic Assessment |
| ||
| Anemia | Blood and lymphatic system disorders | Non-systematic Assessment |
| ||
| COVID-19 infection | Infections and infestations | Non-systematic Assessment |
| ||
| Asthenia | General disorders | Non-systematic Assessment |
| ||
| Blood creatinine increased, | Investigations | Non-systematic Assessment |
| ||
| Dysphagia, | General disorders | Non-systematic Assessment |
| ||
| Erythema | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Pyrexia | General disorders | Non-systematic Assessment |
| ||
| Hyperglycemia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Porphyria non-acute | Hepatobiliary disorders | Non-systematic Assessment |
| ||
| Lipase increased | Investigations | Non-systematic Assessment |
| ||
| Neutropenia | Investigations | Non-systematic Assessment |
| ||
| Odynophagia | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Oral candidiasis | Infections and infestations | Non-systematic Assessment |
| ||
| Pericardial effusion | Cardiac disorders | Non-systematic Assessment |
| ||
| Seborrheic keratosis | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Dyspnea | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Abdominal pain | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Cough | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Malaise | General disorders | Non-systematic Assessment |
| ||
| COVID-19 pneumonia | Infections and infestations | Non-systematic Assessment |
|
The study was terminated (administrative decision) by the sponsor following the withdrawal of idelalisib from the US market for the relapsed FL indication (i.e., not due to any safety reasons emerging from this study).
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Contact ADC Therapeutics | ADC Therapeutics | 954-903-7994 | clinical.trials@adctherapeutics.com |
| Aug 10, 2023 |
| Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D008224 | Lymphoma, Follicular |
| D008223 | Lymphoma |
| ID | Term |
|---|---|
| D008228 | Lymphoma, Non-Hodgkin |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000710749 | loncastuximab tesirine |
| C552946 | idelalisib |
Not provided
Not provided
Not provided
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Participants |
|
| Units |
|---|
| Counts |
|---|
| Participants |
|